Figure 4

Infection of rhesus macaques after vaginal exposure to SP- and SEVI-treated SIVmac. (A) Proportion of infected animals in the three treatment groups as a function of the number of weekly vaginal exposures. (B) Administered viral dose (TCID₅₀) leading to systemic infection and (C) total viral dose (cumulative TCID₅₀) received by the animals until they became systemically infected. Two of the six macaques in the control and SEVI groups and one animal in the SP group are not shown since they remained uninfected after final virus exposure. (D) Peak viral loads during acute infection in the control, SEVI and SP groups.